Join KBI Biopharma, Inc. at BioProcess International: Boston this September! Be sure to stop by Booth #723 to chat with Michael Cavanaugh, Henry Jin, and Brian Newsom. Our scientific team will also be presenting a poster titled A Novel High-Productivity Cell Culture Medium for CHO Bioproduction, and Jake Kim will be presenting a Tech Talk titled Defining a next-generation platform process: production-stage intensification with higher titer and sustained product quality. We look forward to seeing you there!
Tech Talk:
Defining a next-generation platform process: production-stage intensification with higher titer and sustained product quality
Jake Kim, PD Scientist I & Project Leader, Process Development
Poster Presentation:
A Novel High-Productivity Cell Culture Medium for CHO Bioproduction
Atul Joshi, Rick Ottman, Josui Shimada, Sigma Mostafa, Leslie Wolfe, Masayoshi Nagaya, Masaaki Hanamura, Carl Zhang, Keegan Kennedy, Lauren Jillson, and Tiana Ralliford
The industry overall has seen dramatic increases in the productivity of CHO cells due to rapid improvements in cell culture media and upstream process development, but the use of commercial media has inherent limitations when it comes to media optimization requirements. To overcome these limitations, KBI Biopharma's upstream process development team has created a new, high-productivity CHO cell culture medium developed in collaboration between KBI and JSR Life Sciences. This novel medium enables maximum productivity at scale for the development of various biologics and future biomanufacturing.
KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 500+ client partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond.
THE LARGEST BIOPROCESSING EVENT FOR LEARNING HOW TO ACCELERATE PROMISING BIOLOGICS, CELL & GENE THERAPIES TOWARDS COMMERCIAL SUCCESS. Each year, BPI's scientific agenda includes 200+ of the industry's top scientists to present the latest updates on how to improve efficiencies across all phases of biopharmaceutical development and production. Our BPI 2022 agenda includes 8 conference tracks covering novel science across all phases of bioprocessing for biologics, cell & gene therapies.
Visit the conference website >>